Most-Probable-Number-Based Minimum Duration of Killing Assay for Determining the Spectrum of Rifampicin Susceptibility in Clinical Mycobacterium tuberculosis Isolates

Srinivasan Vijay,a,b Hoang Ngoc Nhung,a Nguyen Le Hoai Bao,a Do Dang Anh Thu,a Le Pham Tien Trieu,a Nguyen Hoan Phu,a,c Guy E. Thwaites,a,b Babak Javid,d,e,f Nguyen T. T. Thuonga,b

aOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
bCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
cSchool of Medicine, Vietnam National University of Ho Chi Minh City, Ho Chi Minh City, Vietnam
dCentre for Infectious Diseases and Research, Tsinghua University School of Medicine, Beijing, China
eBeijing Advanced Innovation Center in Structural Biology, Beijing, China
fDivision of Experimental Medicine, University of California, San Francisco, California, USA

Srinivasan Vijay and Hoang Ngoc Nhungh contributed equally to this work. Author order was based on decreasing seniority.

ABSTRACT Accurate antibiotic susceptibility testing is essential for successful tuberculosis treatment. Recent studies have highlighted the limitations of MIC-based phenotypic susceptibility methods in detecting other aspects of antibiotic susceptibilities in bacteria. Duration and peak of antibiotic exposure, at or above the MIC required for killing the bacterial population, has emerged as another important factor for determining antibiotic susceptibility. This is broadly defined as antibiotic tolerance. Antibiotic tolerance can further facilitate the emergence of antibiotic resistance. Currently, there are limited methods to quantify antibiotic tolerance among clinical M. tuberculosis isolates. In this study, we develop a most-probable-number (MPN)-based minimum duration of killing (MDK) assay to quantify the spectrum of M. tuberculosis rifampicin susceptibility within subpopulations based on the duration of rifampicin exposure required for killing the bacterial population. MDK_{90} and MDK_{99} were defined as the minimum duration of antibiotic exposure at or above the MIC required for killing 90 to 99% and 99.99% of the initial (pretreatment) bacterial population, respectively. Results from the rifampicin MDK assay applied to 28 laboratory and clinical M. tuberculosis isolates showed that there is variation in rifampicin susceptibility among isolates. The rifampicin MDK_{99} time for isolates varied from less than 2 to 10 days. MDK was correlated with larger subpopulations of M. tuberculosis from clinical isolates that were rifampicin tolerant. Our study demonstrates the utility of MDK assays to measure the variation in antibiotic tolerance among clinical M. tuberculosis isolates and further expands clinically important aspects of antibiotic susceptibility testing.

KEYWORDS Mycobacterium tuberculosis, rifampicin, antibiotic tolerance assay, minimum duration of killing, most probable number, MDK, MPN, antibiotic tolerance

Tuberculosis (TB), caused by Mycobacterium tuberculosis, results in more than 1.5 million deaths a year (1). Although TB can be successfully treated with antibiotics, a minimum of 6 months of treatment is required (2). Relapse posttreatment and emergence of antibiotic resistance are major negative sequelae of inadequate treatment (2). Success in therapy requires the accurate determination of antibiotic susceptibility and initiation and adherence to an effective antibiotic regimen (3).

The most common measure of antibiotic susceptibility of M. tuberculosis isolates is

Citation Vijay S, Nhung HN, Bao NLH, Thu DDA, Trieu LPT, Phu NH, Thwaites GE, Javid B, Thuong NTT. 2021. Most-probable-number-based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 65:e01439-20. https://doi.org/10.1128/AAC.01439-20.

Copyright © 2021 Vijay et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Nguyen T. T. Thuong, thuongntt@oucru.org.

Received 8 July 2020 Returned for modification 5 August 2020 Accepted 24 November 2020 Accepted manuscript posted online 30 November 2020 Published 17 February 2021
the MIC (4), the concentration of antibiotics that inhibits, kills, or reduces the growth of at least 99% of the bacterial population (5). The MICs for antibiotics vary between clinical *M. tuberculosis* isolates, and epidemiologically relevant MIC breakpoints are used to define *M. tuberculosis* isolates as susceptible or resistant to each antibiotic (6).

However, Colangeli et al. recently showed that MICs in the susceptible range, below the clinical cutoff for resistance, can be associated with poor treatment outcomes in TB (7). Furthermore, recent findings in other bacteria suggest that antibiotic susceptibility differences can even emerge between isolates with similar MICs due to differences in the duration of antibiotic exposure required for killing bacterial subpopulations (8). Therefore, susceptibility or resistance to an antibiotic, defined by the clinical MIC cutoff, is not the only measure of antimicrobial susceptibility, as bacterial isolates can still display widely different susceptibilities to bactericidal antibiotics, a phenomenon broadly described as antibiotic tolerance (8, 9). With antibiotic tolerance, subpopulations of bacteria that are genetically susceptible to an antibiotic are killed more slowly than the bulk population (8). Studies have identified the emergence of mutations in *M. tuberculosis* clinical isolates associated with increased levels of antibiotic tolerance (10–13). The emergence of antibiotic tolerance can further facilitate the emergence of resistance (14–17). These studies highlight limitations of reliance on clinical MIC cutoff alone as the measure of antibiotic susceptibility and the possible role of antibiotic tolerance in poor treatment progression and evolution of antibiotic resistance in *M. tuberculosis* isolates. Hence, it is important to investigate the level of antibiotic tolerance among clinical *M. tuberculosis* isolates defined as susceptible based on clinical MIC cutoffs for resistance.

One way to measure the level of antibiotic tolerance is to determine the duration of antibiotic exposure at or above MICs required for killing the majority of the bacterial population (18). Kill-curve assays allow the study of the dynamics of bacterial population killing after antibiotic exposure (19). Antibiotic-mediated killing of bacterial populations is biphasic, with an initial rapid killing of the majority population followed by a low rate of killing of minority populations, also known as tolerant and persistent bacterial populations (19). Repeated antibiotic exposure can lead to an increase in the level of antibiotic tolerance both at subpopulation and bulk population levels (11, 20). This will further increase the time required for killing the bacterial population. Recent clinical studies have shown in-host evolution of antibiotic tolerance in other pathogenic bacteria and its association with treatment complications (21).

Therefore, quantitative assays to measure the antibiotic tolerance of bacterial populations are required. Commonly used tolerance assays are based on the duration required for killing the bacterial population by antibiotics, also known as the minimum duration of killing (MDK) assay (18). The MDK assay can be used to measure both bulk population and subpopulation levels of antibiotic tolerance (18). MDK_{50} and MDK_{99} refer to the minimum duration required for killing 1 or 2 log_{10} fold (90% to 99%) or the majority of the bacterial population during antibiotic exposure. Hence, MDK_{50} or MDK_{99} can quantify the bulk population level of antibiotic tolerance (18), whereas MDK_{99.99} determines the minimum duration required for killing 4 log_{10} fold of the population and, assuming the tolerant subpopulation is >0.1%, quantifies the subpopulation level of antibiotic persistence (18).

Reliable and feasible methods are required to measure MDK values of clinical *M. tuberculosis* isolates to determine if there are significant variations in antibiotic tolerance among *M. tuberculosis* isolates. A critical measure used in the MDK assay is to accurately determine the viable bacterial numbers at different time points after antibiotic exposure of the bacterial culture. Usually, bacterial viability is measured by either CFU enumeration or most-probable-number (MPN) methods (22). In the MPN method, the viable bacterial numbers in culture are determined by generating 10-fold serial dilutions of the culture until limiting dilution (i.e., the dilutions show no visible bacterial growth over time) is reached. The viable bacterial number (MPN/ml) is calculated by considering that the highest dilution showing growth contains at least one viable...
bacterium and then multiplying by the dilution factor (23). Previous study has shown that MPN and CFU methods give comparable viable counts for *M. tuberculosis* under starvation in phosphate-buffered saline (PBS) (24), whereas only the MPN method can detect differentially detectable *M. tuberculosis* cells generated under rifampicin treatment after initial starvation in PBS, as such *M. tuberculosis* cells fail to grow in the CFU method (24). Furthermore, the MPN method facilitates differentially culturable *M. tuberculosis* growth from clinical samples (25), increasing the count of viable bacteria compared to the CFU method. In addition, all serial dilutions can be simultaneously incubated in one microtiter plate in the MPN method, overcoming the laborious process of plating multiple serial dilutions to obtain countable numbers of colonies using the CFU method (26). Considering these advantages of the MPN method, we applied this method for determining bacterial viability in our MDK assay.

Given the prime importance of rifampicin in drug-sensitive tuberculosis treatment (27), we developed and tested an MPN-based MDK assay for determining the level of rifampicin tolerance among *M. tuberculosis* isolates. We applied this assay on a pilot scale to determine the spectrum of rifampicin susceptibility in 27 clinical *M. tuberculosis* isolates and identified variation in rifampicin susceptibility among these isolates, which included 7 isoniazid- and rifampicin-susceptible isolates, 19 isoniazid-resistant isolates, and 1 multidrug-resistant TB (MDR-TB) isolate, resistant to both isoniazid and rifampicin.

**RESULTS**

Developing an MPN-based MDK assay for determining *M. tuberculosis* rifampicin susceptibility. To develop the MDK assay and to determine rifampicin susceptibility, we initially optimized the assay by testing laboratory strains *M. tuberculosis* H37Rv and *M. bovis* BCG treated with rifampicin in mid-log phase (Fig. 1 and 2A and B).
Both laboratory strains showed rapid killing with 1 μg/ml rifampicin treatment, the cutoff concentration used for defining susceptible and resistant isolates in mycobacterial growth indicator tube (MGIT) culture for clinical isolates (28). The decrease in MPN/ml compared with day 0 in microtiter plates showed an MDK99 time of less than 1 day for M. bovis BCG and between 2 and 3 days after rifampicin treatment for H37Rv with and without bead beating (Fig. 2B). Bead beating to remove bacterial aggregation, in addition to Tween 80 being in the culture media, marginally decreased H37Rv rifampicin tolerance compared to that of cultures with Tween 80 alone (without beads).

Factors influencing rifampicin MDK assay for M. tuberculosis isolates. Some of the factors that need to be considered for the rifampicin MDK assay are the influence of nutrients, such as carbon source, on M. tuberculosis survival and growth in the MDK assay; we determined the M. tuberculosis viable count in the presence or absence of glycerol by the MPN method (see Fig. S1A in the supplemental material). The results showed that the presence of glycerol in the culture medium consistently increased the MPN compared to those of cultures without glycerol, indicating the influence of carbon source on M. tuberculosis viable numbers.

Similarly, washing was done with 7H9T medium to minimize the changes in culture conditions for the bacterium during different steps of the MDK assay. The washing step is critical, and care should be taken to prevent bacterial cell loss during removal of supernatant. The washing must be adequate to remove rifampicin, as residual rifampicin may inhibit M. tuberculosis growth at undiluted or lower dilutions in MPN dilution series (Fig. S1C). These aspects were considered for standardizing optimum washing steps in the MDK assay.

In addition, initially we performed the rifampicin MDK assay using the CFU method for H37Rv (Fig. S2A). Although we observed similar patterns of kill curves for 20 days of rifampicin treatment between CFU and MPN methods (Fig. S2), the CFU method was difficult to apply to a large set of clinical M. tuberculosis isolates, as getting countable numbers of colonies required plating multiple serial dilutions, which became laborious. Therefore, we applied an MPN-based rifampicin MDK assay for clinical M. tuberculosis isolates.

Applying rifampicin MDK assay for clinical M. tuberculosis isolates. We then applied the MDK assay to investigate variation in rifampicin susceptibility among clinical M. tuberculosis isolates (n = 27). Clinical M. tuberculosis isolates were selected based on GeneXpert MTB/RIF results for rifampicin susceptibility and phenotypic drug
FIG 3 Applying rifampicin MDK assay to clinical *M. tuberculosis* isolates. (A and B) rifampicin MDK assay for mid-log-phase cultures of 6 clinical *M. tuberculosis* isolates susceptible to isoniazid and rifampicin (S1 to S6) (A), and 19 isoniazid-resistant isolates (IR1 to IR19) were treated with 2 μg/ml (Continued on next page)
susceptibility testing (DST) by MGIT. For this assay, we included laboratory strain H37Rv (Rv), 7 isoniazid- and rifampicin-susceptible isolates (S1 to S7) (Fig. 3A), 19 isoniazid-resistant but rifampicin-susceptible isolates (IR1 to IR19) (Fig. 3B), and an MDR-TB isolate (R) (Fig. 3A and B), resistant to both isoniazid and rifampicin. For the MDK assay in clinical isolates, we used a higher rifampicin concentration of 2 μg/ml for both H37Rv and clinical M. tuberculosis isolates cultured without bead beating, and survival fraction was determined by the MPN method using a single set of serial dilution at different time points (Fig. 3A to H). The increase in antibiotic concentration increased the duration of maintaining the rifampicin concentration above the clinical susceptibility cutoff of 1 μg/ml in the medium. This extended the duration of the killing phase as well as the range of MDK for determining the rifampicin susceptibility among clinical M. tuberculosis isolates. Survival curves of the laboratory strain H37Rv and the MDR-TB isolate were included, with susceptible and isoniazid-resistant M. tuberculosis isolates, as controls for high rifampicin susceptibility and resistance, respectively (Fig. 3A and B).

All the rifampicin-susceptible M. tuberculosis isolates and H37Rv showed a reduction in viability, i.e., killing phase for 5 to 10 days of treatment compared with MPN/ml at day 0, whereas rifampicin-resistant MDR-TB isolates showed growth or maintenance of MPN/ml compared with day 0 values over 10 days of rifampicin treatment (Fig. 3A and B). From 5 to 10 days of rifampicin treatment, the regrowth phase was observed in most of the clinical M. tuberculosis isolates, potentially representing the outgrowth of de novo rifampicin-resistant cells (15). Since MDK time can be measured only during the killing phase of rifampicin treatment (29), the range of MDK measurements in our assay was restricted from 2 to 10 days of rifampicin treatment for isoniazid-susceptible (Fig. 3A) and -resistant isolates (Fig. 3B).

Although all the cultures were initially diluted to an optical density (OD) of 0.4, significant variation was observed in the initial MPN among clinical isolates. We observed that H37Rv showed the highest initial MPN, whereas clinical isolate initial MPN showed variation within the range of 10^4 fold (Fig. 3A and B). This variation in the initial MPN was probably due to variation in cell size heterogeneity, cell envelope modifications, and clumping among clinical M. tuberculosis isolates. Even though initial MPN among clinical M. tuberculosis isolates showed variation, we could determine the MDK time for each of the isolates based on the time required for 2- and 4-log_10 fold reductions in the MPN compared to its respective initial MPN (Fig. 3C to H).

There was substantial variation in population and subpopulation levels of rifampicin tolerance among susceptible and isoniazid-resistant M. tuberculosis isolates, as determined by approximate MDK_{90} and MDK_{99} times (Fig. 3C to H). To further confirm the robustness and reliability of the MDK assay for determining rifampicin tolerance of clinical isolates, we repeated the assay with 3 to 6 independent biological replicates of 6 strains, representing fully drug-susceptible (S7) and isoniazid-resistant (IR9, IR11, IR12, and IR13) strains and H37Rv (Fig. 3I and Fig. S3). The repeat assay fully recapitulated the observations, again revealing that 3/4 of the isoniazid-resistant isolates had longer MDK times for rifampicin than the fully drug-susceptible isolate (Fig. 3I and Fig. S3). Our data confirm the ability of the MDK assay to discriminate differences in the bulk

FIG 3 Legend (Continued)

rifampicin (B). Viable mycobacterial cell numbers were determined by the MPN method on day 0 (just before rifampicin treatment) and 5 and 10 days after rifampicin treatment. Laboratory strain H37Rv (Rv) and MDR-TB (R) isolates were used as controls for low and high rifampicin tolerance, respectively, with both susceptible and isoniazid-resistant isolates. (C and D) Normalized survival fraction of susceptible (C) and isoniazid-resistant (D) isolates to determine the MDK_{90} and MDK_{99} times. Black solid horizontal lines indicate 2-log_{10} fold (M_{90}) and 4-log_{10} fold (M_{99}) reductions in survival fractions compared to day 0 values (normalized as 100% for susceptible and isoniazid-resistant isolates). Black dashed vertical lines show the approximate time required for 99% or 99.99% reduction in survival fraction of individual M. tuberculosis isolates. (E to G) Susceptible and isoniazid-resistant isolates (from panels A and B) grouped based on decreasing order of their initial MPN counts. (H) M. tuberculosis isolates with initial log_{10} MPN of 6, 5, and 4 grouped together, as there were only a few isolates in each of these groups for MDK time determination. (I) Normalized survival fraction of the H37Rv subset of isoniazid-resistant (IR9, IR11, IR12, and IR13) and a susceptible isolate (S7) at 0, 2, and 5 days after rifampicin treatment (de novo mutations) (Fig. 3I). Black solid horizontal lines indicate 2-log_{10} fold (M_{90}) reduction in survival fraction compared to day 0 values (normalized as 100% for all M. tuberculosis strains). Dashed vertical lines show approximate times required for 99% reduction in survival fraction of individual M. tuberculosis isolates, except for three isoniazid-resistant isolates with high rifampicin tolerance (IR11, IR12, and IR13, M_{90} of >5 days).
population and subpopulation susceptibility and tolerance to rifampicin among clinical M. tuberculosis isolates.

Finally, we investigated the variation in the distribution of rifampicin MDK99 and MDK99.99 times among isoniazid-susceptible and -resistant isolates. H37Rv showed high rifampicin susceptibility, similar to the earlier observation with 1 μg/ml rifampicin treatment, having an MDK99 and MDK99.99 time of less than 2 and 3 days, respectively, whereas for susceptible and isoniazid-resistant clinical M. tuberculosis isolates, MDK99 time distribution varied from 2 to >10 days and MDK99.99 time varied from 3 to >10 days; a value of more than 10 days indicates a high level of rifampicin tolerance beyond the detection limit of our assay (Fig. 4). There was no statistically significant difference between overall rifampicin tolerance distribution, measured as MDK99 and MDK99.99 time, between susceptible and isoniazid-resistant groups (Mann-Whitney U test) (Fig. 4A). We used the median of MDK99 (5 days) and MDK99.99 (10 days) distribution to group susceptible and isoniazid-resistant isolates with low (L-RIF < median) and high (H-RIF > median) rifampicin tolerance. Each data point represents one clinical M. tuberculosis isolate, and median and interquartile ranges of distributions are given (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001; all by Mann-Whitney U test).

**DISCUSSION**

In this study, we developed an MPN-based MDK assay for determining the spectrum of rifampicin susceptibility in clinical M. tuberculosis isolates. Our MDK assay can be easily adapted to study the variation in killing dynamics and determine the susceptibility level for different conditions, such as different concentrations of rifampicin, other antituberculosis antibiotics, combinations of antibiotics, and host stresses or bacterial metabolic adaptations (such as different carbon sources) by changing the treatments accordingly. Our pilot-scale study indicates the presence of bulk population and subpopulation level variation in rifampicin susceptibility among clinical M. tuberculosis isolates, as determined by MDK99 and MDK99.99 times, respectively.

rifampicin-susceptible clinical M. tuberculosis isolates (fully susceptible and isoniazid resistant, n = 26) show variation in MDK time, ranging from less than 2 up to 10 days and greater than 10 days, which is beyond the detection limit of our assay using...
rifampicin at 2 μg/ml. This indicates the MDK assay can distinguish a spectrum of rifampicin susceptibility, ranging from highly susceptible to highly tolerant.

Tolerance or susceptibility assays require reliable methods to determine the survival fractions of bacterial populations at different durations after antibiotic exposure. Previous studies have shown that the MPN method quantitatively works as good as, and sometimes even better than, the CFU method for determining the viability of *M. tuberculosis* (24, 25). In addition, it has the advantage of incubating all serial dilutions, which is essential for determining the antibiotic tolerance among clinical *M. tuberculosis* isolates with wide variations in the spectrum of tolerance. Adopting the MPN method of the MDK assay in 96-well microtiter plates significantly reduces the labor required for testing antibiotic tolerance in large numbers of clinical isolates compared with the CFU method. Furthermore, the MPN method also reduces the time required for reading the results as the presence or absence of growth at each dilution (visual check) compared with the time required for counting colonies in the CFU method.

A striking observation of our study was the relatively increased tolerance to rifampicin in isoniazid-resistant isolates, particularly concerning MDK99.9. Routine laboratory MIC testing can miss such tolerance in clinical isolates (27). Importantly, the association of high rifampicin tolerance with isoniazid resistance may further contribute to the de novo emergence of multidrug resistance or failure of multidrug combinational therapy (17, 30) and requires further detailed investigation. The spectrum and high level of antibiotic tolerance observed in our clinical isolates is in accordance with the in vitro evolution of antibiotic tolerance in laboratory strains of mycobacteria (11) and high levels of antibiotic tolerance observed in other bacteria (31).

This assay has been developed considering laboratories based in low- and middle-income countries, and the growth on the microtiter plate can be read using a simple mirror box. The viability can be detected early using fluorescence dyes to further reduce the incubation time and obtain rapid results for clinical application (32). The MDK assay will also help us to screen for phenotypic antibiotic tolerance among clinical *M. tuberculosis* isolates and identify novel genetic variants and molecular mechanisms associated with the emergence of antibiotic tolerance (10–12). In addition, the MDK assay can help to identify possible chemical agents to reverse such tolerance by increasing the antibiotics potential (16). Investigating antibiotic tolerance and its emergence in clinical *M. tuberculosis* isolates will greatly improve treatment strategies by identifying hard-to-treat phenotypes and stratifying treatment approaches (33), preventing relapse or emergence of antibiotic resistance (17, 30).

**MATERIALS AND METHODS**

**Bacterial isolates.** *M. tuberculosis* H37Rv and *M. bovis* BCG from a laboratory strain collection and clinical *M. tuberculosis* isolates from pulmonary tuberculosis patients, collected before and after treatment for a previous study (34), were revived from the archive and initially cultured in 7H9G medium (supplemented with 10% oleic acid-albumin-dextrose-catalase [OADC], 0.2% glycerol), followed by one or two subcultures in Middlebrook 7H9T medium (BD Difco, Thermo Fisher Scientific) supplemented with OADC and 0.05% Tween 80, with or without 0.2% glycerol. These cultures were used for the MDK experiments.

**Mycobacterium culture for MDK assay.** Mycobacterial isolates were cultured in 10 to 15 ml 7H9T medium in 50-ml tubes, with or without glass beads, in a shaking incubator at 37°C. When the culture reached an OD at 600 nm (OD<sub>600</sub>) range of 0.4 to 0.6, acid-fast staining was done to confirm the purity of the Mycobacterium culture. Cultures set with glass beads were vortexed for 3 min to disrupt bacterial aggregates, as the aggregates may influence the level of antibiotic tolerance (35). Cultures in both sets of tubes, with or without glass beads, were diluted to an OD<sub>600</sub> of 0.4 with fresh 7H9T medium and used for the MDK assay.

**Rifampicin preparation.** Rifampicin (Sigma-Aldrich) stock solutions were prepared in dimethyl sulfoxide and filter sterilized, and aliquots were stored at −20°C for MDK assay.

**Bacterial viability determination by MPN method.** For the MDK assay, first the initial viability of mid-log-phase (OD<sub>600</sub> of 0.4) *M. tuberculosis* cultures were measured by the MPN method (0-day) by taking a 1-ml aliquot from the culture at an OD of 0.4 and harvesting the culture at 7,000 rpm for 5 min. Nine hundred microliters of supernatant was removed carefully without disturbing the bacterial cell pellet, and the cell pellet was washed once by suspending in 1 ml (1× volume) of fresh 7H9T medium, vortexed, and recentrifuged. Nine hundred microliters of supernatant was removed, and the cell pellet again was resuspended in 1 ml fresh 7H9T medium. One hundred microliters from this 1-ml culture was
transferred to 96-well plates as an undiluted culture in triplicate for serial dilution. Ten microliters from this undiluted (10⁰) culture was used for serial dilution in 90 μl 7H9T medium up to 10⁻⁹ dilutions in microtiter plates (Fig. 1). Each time, new pipette tips were used for mixing and transferring culture during serial dilution. The final two wells, with 7H9T medium at the end of serial dilution after 10⁻⁹, were left for sterility check without adding any mycobacterial culture (Fig. 1). The serially diluted plates were sealed by 96-well plastic adhesive seal and incubated at 37°C, without shaking, for 1 or 2 months. Immediately after initial (0-day) viability measurement, the mycobacterial cultures in the 50-ml tubes were treated with rifampicin at a final concentration of 1 or 2 μg/ml, and cultures were further incubated at 37°C with shaking (Fig. 1). At different time points (1, 2, 3, 5, 10, 15, and 20 days, depending on the experiment) after rifampicin treatment, viable bacterial numbers were measured again by removing 1 ml from the rifampicin-treated culture, cells were washed once with 1 ml fresh 7H9T medium (1× volume) to remove rifampicin, and the MPN assay was repeated as performed on the initial day (0-day) before rifampicin treatment (Fig. 1). In addition, we performed the rifampicin MDK assay and viability measurement using the CFU method for H37Rv. For CFU-based viability determination, the same steps were followed as those described for the MPN method, except 50-μl aliquots from different serial dilutions were plated on 7H10 plates and incubated at 37°C, and CFU numbers were counted after 30 days of incubation.

For the MPN method, growth in 7H9T medium at the bottom of 96-well plates was recorded by the Thermo Fisher Sensititre Vizon digital MIC viewing system (Thermo Fisher Scientific, Inc.) after 15 to 20 days and 1 and 2 months of incubation (Fig. 1; see also Fig. S1 in the supplemental material). Final MPN results were calculated based on 15 to 20 days of incubation for antibiotic tolerance determination between clinical isolates considering different factors influencing the MPN (Fig. S1). There was some increase in MPN at 1 month (slow growth possibly due to postantibiotic effect or resuscitation of nonreplicating persisters), and drying up of wells was also observed in 96-well plates at the 1- and 2-month time points (Fig. S1). Early reading at 15 to 20 days clearly distinguished differences in the extent of growth even at the same serial dilution between M. tuberculosis isolates (Fig. S1A). Due to higher sensitivity in detecting differences in growth at 15 to 20 days of incubation and drying up of wells at later incubation periods, we used 15- to 20-day MPN results for calculating the survival fraction after rifampicin treatment (Fig. S1). M. tuberculosis viability at each time point is calculated as mean MPN/ml with 95% CI (confidence intervals) or with standard deviations. For a single set of dilution series, the MPN/ml was determined by the highest dilution showing growth multiplied by the dilution factor. Based on MPN value at each time point, survival curves were plotted to determine the killing dynamics after rifampicin treatment. The survival fraction after rifampicin treatment, MDK₉₉ and MDK₉₉.₉₉ times were calculated based on the duration required for 99% and 99.99% reduction in the survival of the population, respectively, during the killing phase compared to the initial MPN/ml, taken as 100%.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1, PDF file, 0.3 MB.**

**ACKNOWLEDGMENTS**

We thank Saurabh Mishra and Carl Nathan, Department of Microbiology and Immunology at Weill Cornell Medicine, for providing the MPN calculation program.

This work was supported by the Wellcome Trust Intermediate Fellowship in Public Health and Tropical Medicine to N.T.T. (206724/Z/17/Z) and Wellcome Trust Major Overseas Program Funding to G.T. (106680/B/14/Z).

**REFERENCES**

1. World Health Organization. 2019. Global tuberculosis report. World Health Organization, Geneva, Switzerland. https://www.who.int/publications/item/global-tuberculosis-report-2019
2. Horsburgh CR, Jr, Barry CE, III, Lange C. 2015. Treatment of tuberculosis. N Engl J Med 373:2149–2160. https://doi.org/10.1056/NEJMra1413919.
3. Vernon A, Fielding K, Savic R, Dodd L, Nahid P. 2019. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. PLoS Med 16:e1002884. https://doi.org/10.1371/journal.pmed.1002884.
4. Hall L, Jude KP, Clark SL, Wengenack NL. 2011. Antimicrobial susceptibility testing of *Mycobacterium tuberculosis* complex for first and second line drugs by broth dilution in a microtiter plate format. J Vis Exp 52:3094. https://doi.org/10.3791/3094.
5. Parish TRD, Brown AC (ed). 2015. Mycobacteria protocols, 2nd ed. Humana, Totowa, NJ.
6. Angeby K, Jureen P, Kahlmeter G, Hoffner SE, Schon T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for *Mycobacterium tuberculosis*. Bull World Health Organ 90:693–698. https://doi.org/10.2471/BLT.11.096644.
7. Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD,
